|
Oct 9
|
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
|
|
Oct 3
|
Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
|
|
Jul 30
|
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
|
|
Jul 25
|
Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
|
|
Jul 18
|
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
|
|
Jun 24
|
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
|
|
Jun 18
|
Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial
|
|
May 11
|
Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
|
|
May 8
|
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 8
|
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 2
|
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
|
|
May 2
|
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
|
|
May 1
|
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
|
|
Apr 16
|
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
|
|
Apr 15
|
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
|
|
Apr 15
|
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
|
|
Mar 27
|
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
|
|
Mar 20
|
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
|
|
Mar 7
|
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 7
|
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
|